| Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More | Frank Vinluan | 09/04/20 | National |
| Nestlé to Swallow Up Peanut Allergy Drug Maker Aimmune in $2.6B Deal | Frank Vinluan | 08/31/20 | San Francisco |
| Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy | Sarah de Crescenzo | 08/17/20 | New York |
| Freeline Therapeutics and Checkmate Pharma Make Opening IPO Moves | Frank Vinluan | 07/21/20 | Europe |
| Two Days, Six IPOs, and $1B Raised for Biotech Research & More | Frank Vinluan | 07/17/20 | National |
| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases | Frank Vinluan | 07/06/20 | Boston |
| With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash | Sarah de Crescenzo | 06/26/20 | National |
| Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | Sarah de Crescenzo | 05/29/20 | National |
| Encouraging Signals for New Cancer Cell Therapy Strategies | Mandy Jackson | 05/06/20 | National |
| Creating Consistent Value in Biotech Without Diluting Stakeholders | Alexis Peyroles | 04/07/20 | National |
| Fate Inks $100M Deal With Janssen for Stem Cell-Derived Cancer Therapies | Sarah de Crescenzo | 04/03/20 | San Diego |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing | Brenda Sandburg | 03/24/20 | National |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
| Harbour BioMed Tacks on $75M to Advance Broad Biologics Pipeline | Sarah de Crescenzo | 03/12/20 | Boston |
| Silverback Therapeutics Adds $79M to Test HER2+ Tumor-Targeting Drug | Sarah de Crescenzo | 03/11/20 | Seattle |
| Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy | Frank Vinluan | 01/31/20 | San Francisco |
| Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug | Frank Vinluan | 01/13/20 | National |
| Merck Ramps Up KRAS Chase Through Licensing Deal With Taiho, Astex | Frank Vinluan | 01/06/20 | New York |
| No More Fish or Fruit: Intrexon Turns SynBio Focus to Human Health | Frank Vinluan | 01/02/20 | National |
| Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer | Sarah de Crescenzo | 12/10/19 | San Diego |
| Roche Notches FDA Nod in Lung Cancer, Amps Up Competition With Merck | Frank Vinluan | 12/04/19 | San Francisco |
| Ferring and Blackstone Team Up to Fund Gene Therapy Firm With $570M | Frank Vinluan | 11/25/19 | Boston |
| ArsenalBio Launches With $85M for “Programmable” T Cell Therapies | Frank Vinluan | 10/17/19 | San Francisco |
| Eli Lilly Drug Acquired in Armo Deal Fails Pancreatic Cancer Test | Frank Vinluan | 10/16/19 | Indiana |
| ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More | Ben Fidler | 10/01/19 | National |
| Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More | Frank Vinluan | 09/27/19 | National |
| Gilliland to Step Down as Head of Fred Hutch in 2020 | Jeff Buchanan | 09/17/19 | Seattle |
| FDA Doesn’t Shell Peanut Allergy Drug Pre-Hearing, Aimmune Shares Climb | Frank Vinluan | 09/11/19 | San Francisco |
